163 related articles for article (PubMed ID: 36809324)
21. Treating 2 Diseases With 1 Drug: PDE-4 Inhibitor for COPD and Psoriasis.
Michels K; Hagner M; El Zein M; Dasa O; Assaly R
Am J Ther; 2017; 24(1):e103-e104. PubMed ID: 27415981
[No Abstract] [Full Text] [Related]
22. Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study.
Salvesen ØNU; Davidsen JR; Pottegård A; Henriksen DP
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):314-319. PubMed ID: 29569375
[TBL] [Abstract][Full Text] [Related]
23. Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.
Bateman ED; Bousquet J; Aubier M; Bredenbröker D; O'Byrne PM
Pulm Pharmacol Ther; 2015 Dec; 35 Suppl():S11-9. PubMed ID: 26456372
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
25. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
Vollert S; Kaessner N; Heuser A; Hanauer G; Dieckmann A; Knaack D; Kley HP; Beume R; Weiss-Haljiti C
Diabetologia; 2012 Oct; 55(10):2779-2788. PubMed ID: 22790061
[TBL] [Abstract][Full Text] [Related]
26. Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Mackay AJ; Patel ARC; Singh R; Sapsford RJ; Donaldson GC; Prasad N; Goehring UM; Nip TK; Wedzicha JA
Am J Respir Crit Care Med; 2017 Sep; 196(5):656-659. PubMed ID: 28146642
[No Abstract] [Full Text] [Related]
27. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
[TBL] [Abstract][Full Text] [Related]
28. Roflumilast: clinical benefit in patients suffering from COPD.
Ulrik CS; Calverley PM
Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist.
Salvator H; Naline E; Brollo M; Tenor H; Grassin-Delyle S; Devillier P
Fundam Clin Pharmacol; 2021 Aug; 35(4):725-731. PubMed ID: 33145785
[TBL] [Abstract][Full Text] [Related]
30. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
O'Malley P
Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
[No Abstract] [Full Text] [Related]
31. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101
[TBL] [Abstract][Full Text] [Related]
32. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
[TBL] [Abstract][Full Text] [Related]
33. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Zheng J; Yang J; Zhou X; Zhao L; Hui F; Wang H; Bai C; Chen P; Li H; Kang J; Brose M; Richard F; Goehring UM; Zhong N
Chest; 2014 Jan; 145(1):44-52. PubMed ID: 24135893
[TBL] [Abstract][Full Text] [Related]
34. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy.
Egeberg A; Meteran H; Gyldenløve M; Zachariae C
Br J Dermatol; 2021 Dec; 185(6):1251-1252. PubMed ID: 34184248
[No Abstract] [Full Text] [Related]
35. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
36. Roflumilast for asthma: Weighing the evidence.
Bateman ED; O'Byrne PM; Buhl R; Rabe KF
Pulm Pharmacol Ther; 2015 Dec; 35 Suppl():S1-3. PubMed ID: 26278190
[No Abstract] [Full Text] [Related]
37. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Doggrell SA
Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820
[No Abstract] [Full Text] [Related]
38. What is the role of roflumilast in chronic obstructive pulmonary disease?
Lau C; Mehta AC; Hatipoglu U
Cleve Clin J Med; 2017 Jan; 84(1):13-15. PubMed ID: 28084977
[No Abstract] [Full Text] [Related]
39. A randomized, controlled pilot study of oral roflumilast compared with intramuscular methotrexate for plaque and scalp psoriasis.
Saadi DG; El-Komy MHM; Khedr H; Shawky N; Hegazy AA; Azzazi Y; AlOrbani AM
J Am Acad Dermatol; 2024 May; 90(5):1063-1065. PubMed ID: 38266682
[No Abstract] [Full Text] [Related]
40. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Michels G; Erdmann E; Pfister R
Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
